Human Papillomavirus (HPV) genotype 18 variants in patients with clinical manifestations of HPV related infections in Bilbao, Spain
- Sara L Arroyo1,
- Miren Basaras1Email author,
- Elixabete Arrese1,
- Silvia Hernáez2,
- Daniel Andía3,
- Valentín Esteban2,
- Koldo Garcia-Etxebarria4,
- Begoña M Jugo4 and
- Ramón Cisterna1, 2
© Arroyo et al.; licensee BioMed Central Ltd. 2012
Received: 4 June 2012
Accepted: 30 October 2012
Published: 2 November 2012
Human papillomavirus (HPV) variants differ in their biological and chemical properties, and therefore, may present differences in pathogenicity. Most authors classified variants based on the phylogenetic analysis of L1 region. Nevertheless, recombination in HPV samples is becoming a usual finding and thus, characterizing genetic variability in other regions should be essential.
We aimed to characterize the genetic variability of HPV 18 in 5 genomic regions: E6, E7, E4, L1 and the Upstream Regulatory Region (URR), working with both single infection and multiple HPV infection samples. Furthermore, we aimed to assess the prevalence of HPV 18 variants in our region and look for possible existence of recombination as well as analyze the relationship between these variants and the type of lesion.
From 2007 to 2010, Clinical Microbiology and Infection Control Department analyzed 44 samples which were positive for HPV 18. Genetic variability was determined in PCR products and variants were assigned to European, Asian-amerindian or African lineage. Recombination and association of variants with different types of lesion was studied.
Genetic analysis of the regions revealed a total of 56 nucleotide variations. European, African and Asian-amerindian variants were found in 25/44 (56.8%), 10/44 (22.7%) and 5/44 (11.4%) samples, respectively. We detected the presence of recombinant variants in 2/44 (4.5%) cases. Samples taken from high-grade squamous intraepithelial lesions (H-SIL) only presented variants with specific-african substitutions.
Multiple HPV infection, non-european HPV variants prevalence and existence of recombination are considered risk factors for HPV persistence and progression of intraepithelial abnormalities, and therefore, should be taken into consideration in order to help to design and optimize diagnostics protocols as well as improve epidemiologic studies.
Our study is one of the few studies in Spain which analyses the genetic variability of HPV18 and we showed the importance of characterizing more than one genomic region in order to detect recombination and classify HPV variants properly.
KeywordsHuman papillomavirus infection Genotype 18 Variants Recombination Multiple infection
High-grade squamous intraepithelial lesion
Low-grade squamous intraepithelial lesion
Squamous intraepithelial lesion
Upstream regulatory region.
Based on the epidemiologic classification in terms of their risk to induce cervical cancer, human papillomaviruses (HPV) can be divided into 3 groups: “high-risk” genotypes associated with a greater risk of developing cancer, “low-risk” genotypes associated with low grade cell changes or benign epithelium proliferations in the genital area, but not with cancer, and “probable high-risk” genotypes from which there is not enough data about their relationship with cervical cancer to classify them .
About 15 genotypes are classified as high-risk types, and two of them (16 and 18) cause over 70% of all cervical cancer cases [2, 3]. Nucleotide variability of these genotypes has been largely studied and different molecular variants were described [4, 5]. These variants differ in their biological and chemical properties [6–8], and therefore, may become an important risk factor in cervical cancer due to possible differences in pathogenicity.
Most authors classified variants based on the phylogenetic analysis of one genomic region nucleotide variations . Nevertheless, some publications have confirmed the presence of recombination in HPV samples [10, 11]. This event may occur due to a homologous recombination or to a repeated infection of the same HPV genotype but different variant and it is more often found since coinfections with more than one HPV type are becoming a usual finding [12–14]. Therefore, it should be essential to determine HPV variants analyzing different genomic regions and multiple infections.
There are very few epidemiological national studies in Spain and all of them refer to HPV 16 which is the most investigated HPV type worldwide. However, there is no previous national work related to HPV 18 nucleotide variability, which is the second most prevalent HPV genotype found in cervical cancer.
The aim of the present study was: i) to characterize the genetic variability of HPV 18 in 5 genomic regions: E6, E7, E4, L1 and the Upstream Regulatory Region (URR), working with both single infection and multiple HPV infection samples, ii) assess the prevalence of HPV 18 variants in our region and look for existence of recombination, and iii) analyze the relationship between variants and types of lesion.
Since 2007 to 2010, a total of 1085 positive samples for HPV were received and analyzed. HPV 18 was detected in 65 samples (6%). Forty-four patients consented to have their samples analyzed and studied, so this study was based on their samples: 10 single HPV infections (22.7%) and 34 multiple HPV infections (77.3%).
We were able to amplify HPV DNA in 43/44 samples for E6 region, 41/44 for E7, 35/44 for E4, 43/44 for L1 region and 44/44 for URR region. All PCR products were sequenced and sequences from each region were submitted to GenBank.
In the E6 gene nine nucleotide variations were detected. Six of them were specific to the African lineage: T317C (6/10 African variants), T251C (9/10), A548G, G266A and G374A (present in all African isolates) and C342T (5/10 African variants) which lead to a non-synonymous amino acid alteration His/Tyr. A non-synonymous substitution T318C (Tyr/His) was found to be specific to the European lineage (2/25 European isolates), while the synonymous substitution C549A was detected among the three different branches (35/43 sequenced E6 amplimers). In our study, C287G was observed in all HPV 18 isolates.
E7 gene genetic variability analysis revealed five nucleotides substitutions. Three nucleotide variations were specific for the African lineage: C665T (3/10 African variants), C593T (His/Tyr), C640C and T864G (Asn/Ser). All of them but C665T and T864G were present in all African variants. One synonymous substitution (C751T) was detected in both European and Asian-amerindian isolates (26/34 non-African variants).
E4 gene analysis presented most nucleotide variations (17 substitutions) and almost half of them (8/17) lead to amino acid changes. All African variants showed 4 non-synonymous substitutions (C3558A His/Gln, C3578T Ser/Leu, A3586C Ser/Arg and T3593G Ile/Ser), one synonymous variation (T3534C) and a deletion of 6 amino acids (3627–3632). European variants showed 4 specific non synonymous substitutions G3482A (Ser/Asn, 3/25 isolates), T3563A (Leu/Gln, 4/25), C3617T (Ser/Leu, 4/25) and C3630G (His/Gln, all European isolates). Two non-synonymous substitutions were also detected in two European isolates: T3492A and C3615T.
L1 gene and URR sequence analysis demonstrated the presence of substitutions C6842G and T7592C in all our isolates.
Most nucleotide variations found in our study have been already described in literature except for T318C, C665T, C3615T, C3617T, G6897A, G6993A, A7000T/C, T7001C, T7007G and T7765G. Only substitutions in positions 318 and 3617 lead to amino acid changes (Tir/His and Ser/Leu, respectively). T318C substitution was present in 2 European isolates whereas C3617T nucleotide change was not specific to any lineage and was detected in 5 samples.
In our study, the predominant variant found was the European (25/44 samples) followed by the African (10/44) and the Asian-amerindian variants (5/44).
Evidence for recombinant samples
Sample \ Gene
No recombination detected.
Maxchi detected recombination.
(LSCM is one of the donors)
Maxchi detected recombination.
(LSCI and LSCR1 are the donors)
No recombination detected.
No recombination detected.
No recombination detected.
No recombination detected.
No recombination detected.
No recombination detected.
Phylogenetic trees were constructed for each sequenced region from these isolates and we found that samples LSCR, LSMH1, LSC5 and LSM7 belonged to the European branch in all regions and therefore, were classified as Europeans. Isolate LSCB belonged to the European lineage in all regions but in E6 (Asian-amerindian) due to the lack of one nucleotide substitution (C549A). This sample was also classified as European.
Samples LSM3, LSCM, LSCE, LSMK1 belonged to the African branch in some regions but were classified as European in others (Table 1).
RDP , Maxchi  and Chimaera were used for the detection of recombination in these 9 samples and only 2 of them were found to be recombinant, one single (LSMK1) and one multiple HPV infection (LCE) (Table 1). LSCM and LSM3 were classified as X variants (unknown).
Variants, type of lesion and infection type
Out of 44 samples, 32 were classified by pathologists as normal (no lesion was found), 9 samples were diagnosed as L-SIL while presence of H-SIL was detected in 3 specimens.
Human papillomavirus 18 variants vs type of lesion
Variants \ Type of Lesion
Presence of lesions associated with non-European variants was found to be statistically significant (p = 0.01053). Nevertheless, there was not a statistically significant association between type of infections (single vs multiple) and presence of lesions (p = 0.18078).
There are almost no epidemiologic studies about HPV 18 variants carried out in Spain and even though national HPV prevalence is low, it cannot be forgotten that this genotype together with genotype 16 cause 70% of cervical cancer cases.
Many authors confirm that distribution of HPV variants is related to geographic or race distribution [6, 17] and therefore, Spain should expect predominance of European variant, followed by African and Asian-amerindian variants. Our results show concordance with this stating: 25 European variants (56.8%), 10 African (22.7%) and 5 Asian-amerindian variants (11.4%).
HPV 18 has been associated with both recurrent lesions with very bad clinical prognosis  and benign lesions . This fact may reflect the oncogenic potential difference among variants. Hecht et al  identified a HPV 18 variant with lower oncogenic potential due to its absence in cervical cancer but presence in 40% of intraepithelial lesions. Villa et al  suggested that non-European HPV 18 variants persisted more frequently and were more associated with pre-invasive lesions. Since then, most studies confirm that different variants of the same genotype differ in their pathogenic characteristics and therefore, nucleotide substitutions may play an important role. Our study results show concordance with these statements as African variants and variants where most of specific-african substitutions were detected were the only type of variants detected in H-SIL.
Most nucleotide changes reported in our study have been previously described and some of them are of particular importance. In URR, the mutation A41G is located in the Sp-1 binding site and isolates with this nucleotide variation have shown to have an increased transcriptional activity . Variations in positions 41 and 104 modulate Sp1 and YY1 activities and are associated to a higher activity of the E6/E7 promoter. Patients with T104C substitution are less likely to present tumour recurrence . Other nucleotide changes like T7651C, A7658C and C7726T also lay within transcription factor binding sites.
Substitutions C287G, C6842G and T7592C were found in all our isolates. Variation C6842G has been previously reported as error in the original sequence , and H. Arias–Pulido et al. sequenced the original reference HPV 18 plasmid (provided by E-M de Villiers, Deutsches Krebsforschungzentrum, Germany) and observed the substitution T7592C , so it is considered as a sequencing error in the original HPV 18 reference sequence report.
Furthermore, ten “new” nucleotide variations have been detected and two of them were non-synonymous and lead to amino acid changes (T318C and C3617T, Tir/His and Ser/Leu, respectively).
Knowledge on HPV variants and their nucleotide variability is essential for three main reasons: i) nucleotide variations may interfere with the viral oncogenic potential, ii) host cellular immune response can be different when there are substitutions in the amino acids on the viral capsid which may be relevant for the vaccination, iii) HPV infections with a variant may not give immunological protection against a subsequent infection with other variant of the same genotype.
Nowadays, HPV variants recombination has already been described and it is more often found since coinfection with more than one HPV type prevalence is not a unusual finding .
In our study we detected 2 recombinant variants (4.5%) which might have been missed or wrong classified if only amplifying one genomic region. Furthermore, non-recombinant samples as LSCM or LSM3 showed specific-african substitutions in some regions (for example E6) whereas they would be classified as european variants when only analyzing nucleotide variation in URR. Therefore, characterizing more than one genomic region may be essential in order to detect recombination and classify HPV variants properly.
We amplified URR and E6, E7 and L1genes from at least 93% of samples. However, when characterizing E4 region, we were only able to amplify 35 samples. E4 gene is generally disrupted during DNA integration into the host genome and this disruption may explain the inability to amplify E4 gene in some of our samples.
In conclusion, data and knowledge on geographic HPV intratypic variants distribution might help to establish a data base about the diversity and pathogenicity of different HPV variants, which may help to design and optimize diagnostics protocols in order to reduce the disease.
Recruitment of participants
Clinical Microbiology and Infection Control Department at Basurto University Hospital (Basque Country, North of Spain) analyzed samples which were remitted from different Hospital Services, especially the Consultation of Sexually Transmitted Diseases and the Department of Obstetrics and Gynecology, from 2007 to 2010.
All samples were collected from patients with clinical manifestations of HPV related infections. Lesions were classified by pathologists into three categories: negative (no lesion was found), low-grade squamous intraepithelial lesion (L-SIL) or high-grade squamous intraepithelial lesion (H-SIL).
Molecular genotyping was carried out using “Linear Array HPV Genotyping Test” kit (Roche Molecular Diagnostics). In our study, we analyzed positive samples for HPV genotype 18 (both single infections and multiple HPV infections) from patients who had given written, informed consent.
Genomic DNA extraction
DNA extraction was performed by QIAamp DNA mini Kit (Qiagen, Hilden, Germany), according to the manufacturer´s instructions. Extracted DNA was eluted with 200 μl AE buffer and stored at −20°C until amplification.
PCR amplification and sequencing
Polymerase chain reaction characteristics for Human papillomavirus 18
Primer sequence (5′ – 3′)
LCR 1 F
LCR 1 R
LCR 2 F
LCR 2 R
PCR was performed in 30 μl of reaction mixture containing 10 × PCR buffer, 25 mmol/L MgCl2, 25 mmol/L of each deoxynucleoside, 100 pmol/L of sense and anti-sense primer, 5 μl of template DNA and 2,5 U of Taq DNA polymerase (Qiagen).
The thermal program started with a pre-heat of 95°C for 15 min, followed by 35–40 cycles of suitable annealing temperature which depended on the primers and finished with a final extension at 72°C for 10 min (Table 3).
PCR products were confirmed based on specific bands of amplified DNA presence in agarose gel (2%). Afterwards, amplimers were automatically sequenced using the “Big Dye Terminator Cycle Sequencing kit” (Applied Biosystems) according to the manufacturer´s instructions.
For E6, E7, E4 and URR amplicons the same forward specific primers as those used in amplification were chosen as sequencing primers. In the L1 region, a specific primer was used in order to sequence HPV 18 and not other HPV types present in cases of multiple infection (Table 3).
Nucleotide variations, phylogenetic analysis: variants and recombination
HPV sequences were aligned and compared to the HPV 18 prototype sequence which belongs to the Asian-amerindian lineage (accession number NC001357), using BioEdit Sequence Alignment Editor v18.104.22.168 and Clustal W (http://www.genome.jp/tools/clustalw/).
Amplification and sequencing of the samples were repeated to confirm nucleotide variations which were present in less than three isolates.
Sequences were assigned to a lineage on the basis of their similarity to HPV 18 known variant sequences  which belong to Asian-amerindian lineage (GenBank accession numbers: EF202143 - EF202146), African (EF202152 - EF202155) and European lineage (EF202147- EF202149, EF202151). Phylogenetic trees were built using the Bayesian inference method implemented in MrBayes 3.1  and three methods (all implemented in RDP3 ) were used for the detection of recombination (RDP , Maxchi  and Chimaera) to analyze isolates which did not adjust to the clusters.
Association of lesions and variants or infection type (single HPV vs multiple HPV infection) was analyzed. Fisher exact test was used for statistically significant association.
GenBank accession numbers
GeneBank accession numbers for the sequenced isolates
All procedures followed were approved by the appropriate Ethics Commitee related to our institutions (Basurto University Hospital and University of Basque Country) and complied with the guidelines and ethical standards for experimental investigation with human subjects of Helsinki Declaration of 1975, as revised in 2000. All study participants provided written, informed consent.
Authors wish to thank the Department of Health from the Basque Government for supporting this project [project number 2008111058].
- Muñoz N, Castellsague X, de Gonzalez AB, Gissmann L: HPV in the etiology of human cancer. Vaccine 2006, 24:1–10.View Article
- Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al.: Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007, 121:621–632.PubMedView Article
- Muñoz N, Bosch FX, Castellsagué X, Díaz M, de Sanjose S, Hammouda D, et al.: Against which human papillomavirus types shall we vaccinate and screen? the international perspective. Int J Cancer 2004, 111:278–285.PubMedView Article
- Yamada T, Manos MM, Peto J, Greer CE, Munoz N, Bosch FX, et al.: Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J Virol 1997, 71:2463–2472.PubMed
- Ong CK, Chan SY, Campo MS, Campo MS, Fujinaga K, Mavromara-Nazos P, et al.: Evolution of human papillomavirus type 18: an ancient phylogenetic root in Africa and intratype diversity reflect coevolution with human ethnic groups. J Virol 1993, 67:6424–6431.PubMed
- de Araujo Souza PS, Sichero L, Macia PC: HPV variants and HLA polymorphisms: the role of variability on the risk of cervical cancer. Future Oncol 2009, 5:359–370.PubMedView Article
- Sichero L, Ferreira S, Trottier H, Duarte-Franco E, Ferenczy A, Franco EL, et al.: High grade cervical lesions are caused preferentially by non-european variants of HPVs 16 and 18. Int J Cancer 2007, 120:1763–1768.PubMedView Article
- López-Savedra A, González-Maya L, de Ponce León S, García-Carranca A, Mohar A, Lizano M: Functional implication of sequence variation in the long control region and E2 gene among human papillomavirus type 18 variants. Arch Virol 2009, 154:747–754.View Article
- de Villiers EM, Fauquet C, Broker TR, Bernard HU, Zur HH: Classification of papillomaviruses. Virology 2004, 324:17–27.PubMedView Article
- Angulo M, Carvajal-Rodríguez A: Evidence of recombination within human alpha-papillomavirus. Virol J 2007, 4:33.PubMedView Article
- Jiang M, Xi LF, Edelstein ZR, Galloway DA, Olsem GJ, Lin WC, et al.: Identification of recombinant human papillomavirus type 16 variants. Virology 2009, 394:8–11.PubMedView Article
- Méndez F, Muñoz N, Posso H, Molano M, Moreno V, van den Brule AJ, et al.: Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines. J Infect Dis 2005, 192:1158–1165.PubMedView Article
- Tinelli A, Leo G, Dell’Edera D, Storelli F, Galante MM, Guido M, et al.: Molecular methods for a correct diagnosis of multiple HPV infections and clinical implications for vaccine. Int J Gynecol Cancer 2011, 21:545–550.PubMedView Article
- Nielson CM, Harris RB, Flores R, Abrahamsen M, Papenfuss MR, Dunne EF, et al.: Multiple-type human papillomavirus infection in male anogenital sites: prevalence and associated factors. Cancer Epidemiol Biomarkers Prev 2009, 18:1077–1083.PubMedView Article
- Martin DP, Lemey P, Lott M, Moulton V, Posada D, Lefeuvre P: RDP3: a flexible and fast computer program for analyzing recombination. Bioinformatics 2010, 26:2462–2463.PubMedView Article
- Smith J: Analyzing the mosaic structure of genes. J Mol Evol 1992, 34:126–129.PubMed
- Xi LF, Kiviat NB, Hildesheim A, Galloway DA, Wheeler CM, Ho J, et al.: Human papillomavirus type 16 and 18 variants: race-related distribution and persistence. J Natl Cancer Inst 2006, 98:1045–1052.PubMedView Article
- Im SS, Wilczynski SP, Burge RA, Monk BJ: Early stage cervical cancers containing human papillomavirus type 18 DNA have more nodal metastasis and deeper stromal invasion. Clin Cancer Res 2003, 9:4145–4150.PubMed
- Burger R, Monk BJ, Kurosaki T, Anton-Culver H, Vasiley SA, Berman ML, et al.: Human papillomavirus type 18: association with poor prognosis in early stage cancer. J Natl Cancer Inst 1996, 88:1361–1368.PubMedView Article
- Hecht J, Kadish A, Jiang G, Burk R: Genetic characterization of the human papillomavirus (HPV) 18 E2 gene in clinical specimens suggests the presence of a subtype with decreased oncogenic potential. Int J Cancer 1995, 60:369–376.PubMedView Article
- Villa LL, Sichero L, Rahal P, Caballero O, Ferenczy A, Rohan T, et al.: Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasma. J Gen Virol 2000, 81:2959–2968.PubMed
- Rose B, Steger G, Dong XP, Thompson C, Cossart Y, Tattersall M, et al.: Point mutations in SP1 motifs in the upstream regulatory region of human papillomavirus type 18 isolates from cervical cancers increase promoter activity. J Gen Virol 1998, 79:1659–1663.PubMed
- Rose B, Thompson CH, Zhang J, Stoeter M, Stephen A, Pfister H, et al.: Sequence variation in the upstream regulatory region of HPV 18 isolates from cervical cancers. Gynecol Oncol 1997, 66:282–289.PubMedView Article
- Meissner J, et al.: Sequencing errors in reference HPV clones. In Human papillomaviruses. A compilation and analysis of nucleic acid and amino acid sequences. 3rd edition. Edited by: Myers G, Baker C, Munger K. Los Alamos (NM): Theoretical Biology and Biophysics, Los Alamos National Laboratory; 1997:110–123.
- Arias-Pulido H, Peyton CL, Torrez-Martinez N, Anderson DN, Wheeler CM: Human papillomavirus type 18 variant lineages in United States populations characterized by sequence analysis of LCR-E6, E2, and L1 regions. Virology 2005, 338:22–34.PubMedView Article
- Chen Z, DeSalle R, Schiffmn M, Herrero R, Burk RD: Evolutionary dynamics of variant genomes of human papillomavirus types 18, 45 and 97. J Virol 2009, 83:1443–1455.PubMedView Article
- Ronquist F, Huelsenbeck JP: MrBayes 3: Bayesian phylogenetic inference under mixed models. Bioinformatics 2003, 19:1572–1574.PubMedView Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.